摘要
目的:高血压是导致阿尔茨海默氏病(AD)的危险因素,它通常可治愈,并为预防AD提供了可能。血管紧张素II(AngII)的升高是导致高血压的重要原因。血管紧张素Ⅱ对血管内皮功能及脑血流(CBF)有着不利影响,这可能会导致AD。因此,血管紧张素Ⅱ拮抗剂可以降低高血压患者患AD的危险。方法:我们研究了野生型(WT)C57bl/6j a和 AβPPswe/PS1ΔE9 (AβPP/PS1) 小鼠中2个月高压状态(通过渗透微泵输注AngII)对其血液收缩压(SBP)和 CBF的影响,并且之后用两种不同的抗高血压药物治疗,一种为依普罗沙坦(EM, 0.35mg/kg) ,另一种为二氢氯噻(HCT, 7.5mg/kg)。利用尾套体积描记法每月对收缩压进行两次监测,磁共振流动敏感交互式反转恢复灌注成像技术测量CBF。慢性血管紧张素Ⅱ灌注诱导的AβPP/PS和WT 1小鼠都表现为收缩压升高,在海马和丘脑CBF仅在AβPP/PS1小鼠有所降低。AβPP/PS1鼠WT鼠的另一个不同是不管在 高血压还是正常血压状态下,WT鼠的SBP要更高。除此之外,对AβPP/PS1小鼠来说,两种抗高血压药对降低AngII诱导的高血压使其恢复正常水平的效果并不明显,而对WT小鼠却十分有效。结论:转基因模型AD中,AngII诱导的SBP升高导致脑血流量异常,使对降压治疗响应减少。结果表明,在AD小鼠模型中,中年高血压患者和脑血流量减少的关系可以类比至人类AD患者身上。该小鼠模型可以用来研究寻找预防和治疗AD的方法。
关键词: 阿尔茨海默病、血管紧张素Ⅱ、血管紧张素Ⅱ受体阻断剂、脑血管循环、利尿剂、高血压。
Current Alzheimer Research
Title:Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Volume: 12 Issue: 10
Author(s): Maximilian Wiesmann, Carmen Capone, Valerio Zerbi, Laura Mellendijk, Arend Heerschap, Jurgen A.H.R. Claassen and Amanda J. Kiliaan
Affiliation:
关键词: 阿尔茨海默病、血管紧张素Ⅱ、血管紧张素Ⅱ受体阻断剂、脑血管循环、利尿剂、高血压。
摘要: Aims: Hypertension, a risk factor for Alzheimer’s disease (AD), is a treatable condition, which offers possibilities for prevention of AD. Elevated angiotensin II (AngII) is an important cause of essential hypertension. AngII has deleterious effects on endothelial function and cerebral blood flow (CBF), which may contribute to AD. AngII blocking agents can thus provide potential candidates to reduce AD risk factors in hypertensive patients. Methods: We studied the effect of 2 months induced hypertension (AngII-infusion via osmotic micropumps) on systolic blood pressure (SBP) and CBF in 10 months-old wild-type (WT) C57bl/6j and AβPPswe/PS1ΔE9 (AβPP/PS1) mice, and treatment with two different antihypertensives, 1) eprosartan mesylate (EM, 0.35mg/kg) or 2) hydrochlorotiazide (HCT, 7.5mg/kg), after 1 month of induced-hypertension. SBP was monitored twice each month via tail cuff plethysmography. CBF was measured with MR by flow-sensitive alternating inversion recovery. Results: Chronic AngII-infusion induced an increase in SBP in both AβPP/PS1 and WT mice accompanied by a decrease in hippocampal and thalamic CBF only in the AβPP/PS1 mice. An additional difference between the AβPP/PS1 mice and WT mice was that SBP was much higher in AβPP/PS1 mice in both hypertensive and normotensive conditions. Moreover, both antihypertensives were less effective in reducing AngII-induced hypertension to normal levels in AβPP/PS1 mice, while being effective in WT mice. Conclusions: It can be concluded that AngII-induced elevated SBP results in impaired CBF and a decreased response to blood pressure lowering treatment in a transgenic model of AD. Our findings suggest a relation between midlife hypertension and decreased CBF in an AD mouse model, similar to the relation which has been found in AD patients. This translational mouse model could be used to investigate possible prevention and treatment strategies for AD.
Export Options
About this article
Cite this article as:
Maximilian Wiesmann, Carmen Capone, Valerio Zerbi, Laura Mellendijk, Arend Heerschap, Jurgen A.H.R. Claassen and Amanda J. Kiliaan , Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (10) . https://dx.doi.org/10.2174/1567205012666151027130135
DOI https://dx.doi.org/10.2174/1567205012666151027130135 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology The Role of Nitric Oxide on Endothelial Function
Current Vascular Pharmacology Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design Fabrication and Characterization of Ocular Phase Transition Systems for Blepharitis: A Novel Approach
Drug Delivery Letters Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Use of Antihistamines in Ocular Therapy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Experimental Study of Therapeutic Efficacy of the Topical Preparation «Kourochitin» in Skin Allergy
Letters in Drug Design & Discovery Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design The Effect of Serotonin 5-HT2 Receptor Inhibitor on Vasomotor Responses
Vascular Disease Prevention (Discontinued) Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry The anti-inflammatory agents Siblings Nitroxyl (HNO) and Nitric Oxide (NO) in Cardioprotection
Drug Design Reviews - Online (Discontinued) Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan
Current Drug Delivery The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology